Recursion appoints Najat Khan as CEO, effective January 1

Recursion announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, as CEO and President. Najat will also continue in her role as a member of the Board of Directors. Chris Gibson, current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Advisor Rob Hershberg, Recursion’s current Chairman, will transition to Vice-Chairman and Lead Independent Director. Khan is an accomplished biopharma leader with a proven record of advancing a bold, AI-native approach to discovering, developing, and delivering novel medicines for patients with unmet needs. She brings a unique ability to integrate scientific discovery, data and technology, and business strategy – experience gained across both large pharma and TechBio – to drive meaningful innovation and impact. Since joining Recursion in 2024 as the Chief R&D and Chief Commercial Officer, Khan has delivered bold vision with disciplined leadership to advance value and impact. Khan holds a Ph.D. in Organic Chemistry from the University of Pennsylvania, an AI/ML Certification from MIT’s Computer Science and Artificial Intelligence Laboratory, and a B.A. in Computational Chemistry from Colgate University.